Venetoclax is an oral medication that targets and inhibits the B-cell lymphoma 2 (BCL-2) protein, which plays a crucial role in regulating apoptosis (programmed cell death). Overexpression of BCL-2 is common in various types of cancer, allowing cancer cells to evade apoptosis and continue growing. By inhibiting BCL-2, venetoclax helps to restore the apoptotic process, leading to the death of cancer cells.
